Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Decreased by Federated Hermes Inc.

Federated Hermes Inc. decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 37.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 92,608 shares of the biopharmaceutical company's stock after selling 55,896 shares during the period. Federated Hermes Inc. owned 0.07% of Alnylam Pharmaceuticals worth $22,504,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Gilbert & Cook Inc. increased its position in Alnylam Pharmaceuticals by 7.7% during the 4th quarter. Gilbert & Cook Inc. now owns 4,443 shares of the biopharmaceutical company's stock worth $850,000 after purchasing an additional 317 shares in the last quarter. QRG Capital Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $211,000. Dimensional Fund Advisors LP raised its position in shares of Alnylam Pharmaceuticals by 6.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 267,034 shares of the biopharmaceutical company's stock valued at $51,126,000 after buying an additional 15,123 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 7.0% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company's stock valued at $262,000 after buying an additional 89 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Alnylam Pharmaceuticals by 7.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 56,144 shares of the biopharmaceutical company's stock worth $10,703,000 after acquiring an additional 3,665 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Barclays boosted their price target on Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the company an "overweight" rating in a report on Friday, August 2nd. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their target price for the stock from $198.00 to $370.00 in a research report on Friday, August 16th. JPMorgan Chase & Co. raised their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a "neutral" rating in a research note on Monday, August 26th. Evercore ISI upped their price objective on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday, June 25th. Finally, Cantor Fitzgerald reissued a "neutral" rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, September 9th. Seven investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $279.14.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded up $5.10 during midday trading on Monday, hitting $270.37. 485,734 shares of the stock were exchanged, compared to its average volume of 892,656. The company has a 50 day moving average price of $258.53 and a two-hundred day moving average price of $195.09. The firm has a market cap of $34.71 billion, a P/E ratio of -100.77 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. During the same quarter last year, the firm posted ($2.21) EPS. The company's revenue was up 107.0% compared to the same quarter last year. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares in the company, valued at $20,563,480. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at $20,563,480. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David E. I. Pyott sold 32,450 shares of the company's stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the sale, the director now owns 136 shares in the company, valued at approximately $30,013.84. The disclosure for this sale can be found here. In the last three months, insiders sold 103,148 shares of company stock worth $25,658,824. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.